Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA approval didn't stop AF when amrn received their approval. He just adjusted his narrative and continued his attacks and they were effective. I'm not giving him credit for those results as he just provides the necessary narrative the hedge funds need to justify their actions. The point being, when nwbo receives approval we can expect the drumbeat to continue and I'm not sure there's anything mgt can do to stop it barring a massive win in the lawsuit. But I'm sure there will be those here who are happy to point the finger at nwbo mgt.
Diner is appropriate. Pigs at the government trough.
Does it go well with the handbag?
This raises the question of how you could know if the shares you payed for are real or not.
Good stuff
LD: Tell us about the other cases you’re working on.
LP: I’m involved in a spoofing case we’ve brought on behalf of Northwest Biotherapeutics, a clinical stage biotech company developing lifesaving cancer vaccines, against a number of institutions, including Citadel, one of the world’s largest market makers.
The case is still in its early stages, but for context it’s a classic good guy vs. bad guy story.
Our client alleges that Citadel and the other defendants engaged in spoofing and manipulated the price of its shares, inducing other market participants to buy or sell at artificial prices. By repeatedly and brazenly manipulating the market through spoofing, Citadel and the other defendants directly impacted the price of Northwest Biotherapeutics’ shares, causing the company significant losses as it sold 49 million shares at artificially depressed prices.
Because of the defendants’ alleged spoofing, Northwest Bio, which has a proven, groundbreaking cancer vaccine awaiting FDA approval, has been unable to raise money at prices that should reflect its true value. Instead, its stock price has been gravely affected and the company has often struggled to survive, let alone bring its life extending drugs to market.
LD: Why is this case important?
LP: The facts that underpin the Northwest Biotherapeutics case are not limited to just one company or even one industry or one market. It’s much broader in scope and has a significant impact on market confidence more generally. It’s about markets not reflecting true supply and demand and what stock prices should be. It’s about high-frequency trading and algorithmic trading programs being used to manipulate markets in milliseconds.
LD: It sounds like this could be trailblazing case?
LP: Yes, high-frequency trading and algorithms are rapidly evolving and becoming more sophisticated, making manipulation easier, putting investors at greater risk and garnering the attention of law enforcement. Further, unlike most traditional securities class actions involving misstatements and omissions, these claims are brought under 10b-5(a) and (c), a relatively uncharted area of the law.
Solo? It says they're acting on behalf of of all defendants except one.
Any truth to this?
Want to know why we do not get updates? $NWBO DCXAX-L Why are we so manipulated?
— Nix (@KryptyPop) June 13, 2023
Why are we a $.70 stock? Why so much FUD? Why the delays? Why why why? Here is the answer! pic.twitter.com/KK22PqAd9O
Taking out stop losses?
Thanks.
The link isn't working
I would love to know why the run up on no news is happening. Is it because the spoofing has stopped?
Approval is coming. And when it does its bad news for shorts
He's correct. It's the same signage from years past and all you would have to do to confirm it is read the replies in the tweet.
Someone wants a settlement. 🧐
— Always Watching (@mightynio) May 29, 2023
I suppose that's one way to redefine and redirect attention away from today's expected lack of a mention of not only nwbo but also the science behind it.
I've figured it out. The 3 million is to buy 100,000 left over tote bags. You're welcome.
Best case then, maybe it's the investment group touted by Maverick. I don't recall the name but they supposedly invest mainly in biotech.
The case will go to discovery.
Or settlement, which is what I'm hoping for. The 10Q made it clear the company is cash strapped and a quick settlement would bolster the bottom line.
When was compassionate use approved? The date slips my mind but I don't believe that revenue for the quarter covered three full months. It's prorated I believe. Also, with regard to submissions regulatory approval with regard to the NHRA or were they referring to the FDA?
Disclaimer: I haven't read the 10Q
🚨BREAKING NEWS🚨
— InvestorTurf (@InvestorTurf) May 9, 2023
Doug Cifu, the CEO of Virtu, has stated that he is not familiar with the term "barcoding" as it pertains to the stock market. He has also denied accusations that Virtu and Citadel control stock prices and acknowledged that there are several claims made by…
MHRA recently delayed approval of a drug for a particular indication because the company indicated it lacked capacity to meet forecast need. Automated production of dcvax is critical and I believe relying on a build out for manual production would delay approval for a very long time. Perhaps too long. Flaskworks is the long pole in the tent right now.
The naked short excuse put me in the emergency room.
Shrinkage
🚨BREAKING NEWS🚨
— InvestorTurf (@InvestorTurf) May 1, 2023
A New York judge has signed an order requiring FINRA to appear in court on May 30th to discuss Blue Sheet Data and Naked Shorting.
Probably an indication of where they want to take the stock today.
Its a rehash of the same refuted critiques from the past year. AF could have written this.
Thanks. That doesn't indicate there's been a rolling submission though. Although you'd suspect (hope) that was the case.
Do you have information that there's been a rolling review or is that an assumption on your part?
No volume. Navel gazing
It has been speculated here that checkpoint inhibitors could be prescribed off label. You would probably be better able to address that than anyone here.
Yes, they can. In fact that's the preferred outcome for them.
Based on everything I'm reading here today I expect the share price to continue to drop. I don't intend to sell anything into a decline though. This is the only investment I'm in right now and everything else is in a money market account. It's all in Schwab and frankly I'm more worried about Schwab going forward than I am about nwbo.
There will have to be a ramp up soon just to generate cash flow. There's no way they can service their debt or meet payroll without it.
I'm aware of that but wondered why nwbo acquired financing from a toxic lender after Maverick floated that suggestion. If the financing from the lender you refer to was in the offing it's certainly not immediately available.
Do you think nwbo will be able to finance such expansion? It will be a while before the company is even cash flow positive let alone profitable and banks have reduced lending. Bank liquidity is in pretty bad shape right now.
LP called for the Sturm und Drang.
AF doesn't have to make sense. He's just the frontrunner for the hedge funds attempts to drop the share price. You shouldn't think that just because everyone here understands he's wrong he won't have any impact. I expect next week to be interesting. Interesting in the meaning of the old Chinese saying.
If this was a criminal prosecution their response might be different. As it is they only need to worry, worst case, how much the award, if any, will be. They can probably make many times whatever the award will be while waiting on a resolution.
Hmm. Using historical controls. I thought that was a no no.
And yet it was approved. As was aduhelm.